# Oyster Peptide-Ferrous Chelate Preparation Optimization Structural Characteristics and Enhanced Bioavailability

**Authors:** Yijiu Zhang, Qi Yang, Ximing Yang, Shuzhen Cheng, Ming Du

PMC · DOI: 10.3390/foods15020362 · 2026-01-20

## TL;DR

A new iron supplement made from oyster peptides shows better absorption and fewer side effects than traditional iron supplements.

## Contribution

A novel oyster peptide-ferrous chelate with optimized preparation and enhanced bioavailability is developed.

## Key findings

- OP-Fe achieved 76.07% iron absorption in Caco-2 cells, outperforming ferrous sulfate.
- Optimal preparation conditions yielded a stable chelate with 15.44 g/kg iron content.
- In vivo studies showed higher iron accumulation and upregulated absorption-related genes.

## Abstract

Iron deficiency anemia remains a global nutritional challenge due to the low bioavailability and side effects of conventional inorganic iron supplements. A novel organic iron supplement, oyster peptide ferrous chelate (OP-Fe), was prepared using oyster peptides as ligands. Its preparation process was optimized via single-factor experiments and statistical methods with the optimal conditions identified as 1% peptide concentration, 35 °C chelation temperature, 3.91:1 peptide-to-iron ratio, 1.49% ascorbic acid concentration and pH 6.05. Under these conditions, the chelate’s iron content reached 15.44 ± 0.18 g/kg. Multi-dimensional characterization confirmed that Fe2+ formed stable complexes with oyster peptides through carboxyl, amino, and imidazole groups. In vitro Caco-2 cell experiments showed OP-Fe achieved a maximum iron absorption rate of 76.07%, significantly higher than ferrous sulfate (52.39%). In vivo pharmacokinetic studies in mice demonstrated higher iron accumulation in serum and small intestine for OP-Fe. Key iron transport-related genes (PEPT1, TFR1, DMT1) were upregulated, contributing to enhanced absorption. OP-Fe exhibits favorable structural stability and bioavailability, holding potential as an efficient iron supplement.

## Linked entities

- **Genes:** SLC15A1 (solute carrier family 15 member 1) [NCBI Gene 6564], TFRC (transferrin receptor) [NCBI Gene 7037], DMRT1 (doublesex and mab-3 related transcription factor 1) [NCBI Gene 1761]
- **Chemicals:** ferrous sulfate (PubChem CID 24393), ascorbic acid (PubChem CID 9888239)
- **Diseases:** iron deficiency anemia (MONDO:0001356)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** DMRT1 (doublesex and mab-3 related transcription factor 1) [NCBI Gene 1761] {aka CT154, DMT1}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, SLC15A1 (solute carrier family 15 member 1) [NCBI Gene 6564] {aka HPECT1, HPEPT1, PEPT1}
- **Diseases:** Iron deficiency anemia (MESH:D018798)
- **Chemicals:** Fe2+ (-), iron (MESH:D007501), ferrous sulfate (MESH:C020748), ascorbic acid (MESH:D001205), peptide (MESH:D010455), imidazole (MESH:C029899)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12840548/full.md

---
Source: https://tomesphere.com/paper/PMC12840548